Want to see RXST full AI Analyst Report?
RXST Stock Chart & Stats
$7.61
-$1.16(-3.26%)
At close: 4:00 PM EST
$7.61
-$1.16(-3.26%)
Day’s Range― - ―
52-Week Range$4.48 - $13.22
Previous CloseN/A
Volume110.15K
Average Volume (3M)1.35M
Market Cap
$221.06M
Enterprise Value$183.26M
Total Cash (Recent Filing)$217.88M
Total Debt (Recent Filing)$10.83M
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Aug 05, 2026EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.13
Shares Outstanding41,396,610
10 Day Avg. Volume2,019,012
30 Day Avg. Volume1,352,956
Financial Highlights & Ratios
PEG Ratio-0.32
Price to Book (P/B)1.56
Price to Sales (P/S)3.19
P/FCF Ratio-22.18
Enterprise Value/Market Cap0.83
Enterprise Value/Revenue1.44
Enterprise Value/Gross Profit1.87
Enterprise Value/Ebitda-4.24
Forecast
1Y Price Target
$8.50Price Target Upside11.70% Upside
Rating ConsensusHold
Number of Analyst Covering8
EPS Forecast (FY)-1.36
Revenue Forecast (FY)$131.52M
Bulls Say, Bears Say
Bulls Say
Strategic Alcon CollaborationThe non‑exclusive Alcon partnership provides durable funding ( $60M upfront plus milestones) and global commercialization scale. Alcon’s go‑to‑market reach plus RxSight’s development/manufacturing role and royalty upside materially lowers funding needs and accelerates global adoption over multiple years.
High Product-level Gross MarginsSustained high gross margins from LAL sales indicate structurally attractive unit economics. Strong per‑procedure margins provide a durable profit buffer as volumes scale, permitting reinvestment into commercial expansion and R&D while improving prospects for eventual operating leverage and long‑term profitability.
Conservative, Low-Leverage Balance SheetA well‑capitalized, low‑debt balance sheet gives RxSight flexibility to fund operations, manufacturing scale, and development obligations from the Alcon deal without immediate refinancing pressure. This structural financial strength reduces insolvency risk and supports multi‑year commercial rollouts.
Bears Say
Negative Operating And Free Cash FlowPersistent negative OCF and FCF mean the company is not yet self‑funding growth and must rely on external capital, partnerships, or milestones. Over a 2–6 month horizon this constrains discretionary investment, raises dilution/default risk, and limits the pace at which commercial infrastructure can be scaled.
Recent Revenue SlowdownSequential and year‑over‑year revenue declines reflect adoption headwinds and weaker capital placements. Slowing top‑line growth undermines operating leverage, prolongs reliance on external funding, and delays margin absorption benefits tied to higher production volumes and broader market penetration.
Weak Capital Equipment Placements (LDD)Limited LDD placements constrain the network of providers able to offer post‑operative adjustments, slowing recurring LAL consumable demand. Capital placement weakness reduces channel expansion, delays clinical adoption momentum, and makes revenue growth more dependent on fewer high‑utilization sites.
RxSight News
RXST FAQ
What was Rxsight, Inc.’s price range in the past 12 months?
Rxsight, Inc. lowest stock price was $4.48 and its highest was $13.22 in the past 12 months.
What is Rxsight, Inc.’s market cap?
Rxsight, Inc.’s market cap is $221.06M.
When is Rxsight, Inc.’s upcoming earnings report date?
Rxsight, Inc.’s upcoming earnings report date is Aug 05, 2026 which is in 26 days.
How were Rxsight, Inc.’s earnings last quarter?
Rxsight, Inc. released its earnings results on May 06, 2026. The company reported -$0.38 earnings per share for the quarter, missing the consensus estimate of -$0.299 by -$0.081.
Is Rxsight, Inc. overvalued?
According to Wall Street analysts Rxsight, Inc.’s price is currently Undervalued.
Does Rxsight, Inc. pay dividends?
Rxsight, Inc. does not currently pay dividends.
What is Rxsight, Inc.’s EPS estimate?
Rxsight, Inc.’s EPS estimate is -0.35.
How many shares outstanding does Rxsight, Inc. have?
Rxsight, Inc. has 41,396,610 shares outstanding.
What happened to Rxsight, Inc.’s price movement after its last earnings report?
Rxsight, Inc. reported an EPS of -$0.38 in its last earnings report, missing expectations of -$0.299. Following the earnings report the stock price went down -14.454%.
Which hedge fund is a major shareholder of Rxsight, Inc.?
Currently, no hedge funds are holding shares in RXST
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
RxSight Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$8.50 (11.70% Upside)
$8.50 (11.70% Upside)
Blogger Sentiment
Bullish
RXST Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 148.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 7.2%
Last 30 Days ▲ 7.2%
News Sentiment
Bullish
Bullish news 71%
Bearish news 29%
Bearish news 29%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-36.10%
12-Months-Change
Fundamentals
Return on Equity
-17.01%
Trailing 12-Months
Asset Growth
-2.89%
Trailing 12-Months
Company Description
Rxsight, Inc.
As a medical technology enterprise, RxSight, Inc. (which operated as Calhoun Vision, Inc. until its rebranding in February 2017) specializes in the innovation, manufacturing, and distribution of light-adjustable intraocular lenses (LALs). These advanced lenses are specifically designed for use in cataract surgery, serving patients in both domestic and international markets. The cornerstone of the company's offerings is the RxSight system, a sophisticated solution that enables ophthalmologists to precisely tailor and enhance a patient's visual acuity following cataract removal. An integral part of this system is the RxSight light delivery device, an in-office instrument. This device emits UV light in a carefully controlled pattern to modify the LAL, thereby ensuring optimal visual correction after the surgical procedure. RxSight's primary clientele consists of eye surgeons specializing in cataract treatments. The company was founded in 1997 and its corporate headquarters are situated in Aliso Viejo, California.
RXST Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed picture: operational positives include stabilized LAL procedure volumes, improved gross margin in Q1, a major commercial milestone (300,000 implants), early signs of success from customer reengagement programs, and maintained full-year revenue guidance. Offsetting these are sizable near-term challenges — an 18% YoY revenue decline, weak LDD capital placements (only 20 sold), a Q1 net loss of $15.9M, increased SG&A/OpEx investments, and anticipated margin pressure from higher-cost inventory that will weigh on near-term profitability. Management projects gradual sequential improvement and is investing to drive longer-term growth, but near-term financial headwinds and modest 2026 volume expectations temper the outlook.View all RXST earnings summariesRXST Stock 12 Month Forecast
Average Price Target
$8.50
▲(11.70% Upside)
Technical Analysis
Delcath Systems
―
Senseonics Holdings
―
Butterfly Network
―
NeuroPace
―
Ceribell, Inc.
―
Ownership Overview
6.36% Insiders
15.45% Mutual Funds
23.90% Other Institutional Investors
40.75% Public Companies and
Individual Investors